Bill Text: NY A00572 | 2017-2018 | General Assembly | Introduced
Bill Title: Relates to the tampon safety and research act and its creation of a research program to determine the risks posed from potential toxins in feminine hygiene products.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2018-01-03 - referred to health [A00572 Detail]
Download: New_York-2017-A00572-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 572 2017-2018 Regular Sessions IN ASSEMBLY January 9, 2017 ___________ Introduced by M. of A. ROSENTHAL -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to the creation of a research program to determine the risks posed from potential toxins in feminine hygiene products; and providing for the repeal of such provisions upon expiration thereof The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Short title. This act shall be known and may be cited as 2 "the tampon safety and research act". 3 § 2. Title 6 of article 2 of the public health law, as added by chap- 4 ter 342 of the laws of 2014, is amended by adding a new section 267 to 5 read as follows: 6 § 267. Tampon safety and research. 1. For purposes of this section, 7 the term "feminine hygiene products" means tampons, pads, liners, cups, 8 sponges, douches, wipes, sprays, and similar products used in conjunc- 9 tion with respect to menstruation or other genital-tract secretions. 10 2. The commissioner shall provide for the conduct or support of 11 research by the department to determine the extent to which the presence 12 of dioxins, synthetic fibers, chlorine, and other components (including 13 contaminants and substances used as fragrances, colorants, dyes, and 14 preservatives) in tampons and other feminine hygiene products: 15 (a) poses any risks to the health of individuals who use the products, 16 including risks relating to cervical cancer, endometriosis, infertility, 17 ovarian cancer, breast cancer, immune system deficiencies, pelvic 18 inflammatory disease, toxic shock syndrome, and bacterial and yeast 19 infections; and 20 (b) poses any risks to the health of biological children born to indi- 21 viduals who used such products during or before the pregnancies 22 involved, including risks relating to fetal and childhood development. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD01938-01-7A. 572 2 1 3. Research under subdivision two of this section shall include 2 research to confirm the data on tampons and other feminine hygiene 3 products submitted to the United States food and drug administration by 4 manufacturers of such products. 5 4. Such research projects shall be completed within four years of the 6 effective date of this section. 7 5. Within one year of the completion of such research, any conclu- 8 sions, recommendations and proposals for implementing such recommenda- 9 tions shall be transmitted to the governor, the temporary president of 10 the senate, the speaker of the assembly, the chair of the senate health 11 committee, and the chair of the assembly health committee, and shall 12 also be made available to the public. 13 § 3. This act shall take effect on the ninetieth day after it shall 14 have become a law and shall expire and be deemed repealed five years 15 after such date.